The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.
A 20-year-old male experienced early hair thinning due to male pattern baldness and successfully thickened his hair using oral finasteride and topical minoxidil. The conversation highlights the importance of early action and overcoming fear of medication side effects.
Hair loss theories discussed include poor blood flow, scalp tension, inflammation, and DHT. Treatments mentioned are massaging scalp, minoxidil, finasteride, and RU58841.
A Spanish dermatologist suggests sulforaphane for androgenetic alopecia (AGA) due to its potential to remove DHT metabolites, though high dosages are needed. A topical formulation might be possible.
Scientists discovered a new T cell treatment that could regrow hair. Users are skeptical but hopeful, with some relying on finasteride and minoxidil in the meantime.
AMP-303, a new injectable treatment for androgenetic alopecia, showed promising results in increasing hair count and density with minimal side effects. The treatment demonstrated significant hair regrowth and durability, offering new hope for those with hair loss.
KX-826, Breezula, PP405, and Stemson are potential future treatments for hair loss, with varying timelines and mechanisms like blocking DHT and stem cell activation. Users express skepticism about the timeline and mention current options like hair transplants and minoxidil.
The user discusses using dutasteride to stop hair loss and bimatoprost for regrowth. They plan to use VEGF with hydrogels for potentially permanent hair follicle improvement and suggest PRP as an alternative.
PP405 is a new hair loss treatment facing mixed reactions due to initial hype and insufficient data. Some are hopeful, but many doubt its effectiveness compared to minoxidil and finasteride.
The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.
PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.
The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It jokingly suggests the creation of a new chemical called RU99999.
Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.
The user is experiencing severe side effects from finasteride, including sleep issues, depression, and gynecomastia, and is considering stopping the medication. They are exploring other treatments like RU58841 and dutasteride but are hesitant due to potential side effects.
Minoxidil works by opening potassium channels, leading to reduced blood pressure and potential side effects like reflex tachycardia. It is used for hair growth and affects blood pressure at high doses.
A 16-year-old diagnosed with male pattern baldness (MPB) was prescribed hair vitamins, vitamin D, a non-ketoconazole shampoo, and redenysl + serum, with a suggestion for GFC or IHRF treatments. Some users recommended minoxidil, ketoconazole, and derma stamping, while others advised against certain treatments until the age of 18.
Finasteride and minoxidil are praised for effectively treating hair loss, with users sharing positive experiences and some discussing side effects. Others express concerns about limited treatment options and the need for more research and alternatives.
A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.
PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
Exosomes are being considered for hair regrowth, with some users reporting initial improvement. One user moved on to using dutasteride and oral minoxidil with positive results.
Magnesium L-Threonate may help treat balding by reducing DKK-1 expression without affecting DHT. Users discuss its potential effectiveness and application methods, with some considering trying it topically.
RU58841's side effects may be exaggerated due to anxiety, with some users experiencing no issues and others reporting symptoms like chest pain. RU58841, minoxidil, and finasteride are used for hair loss treatment, with varying individual reactions.
Genetic factors, enzyme activity, and DHT sensitivity affect individual responses to hair loss treatments like finasteride, minoxidil, and dutasteride. Starting treatments early can slow hair loss, but results vary among individuals.
PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
Finasteride and dutasteride can affect sexual function, cognition, and mood. Alternatives like minoxidil, pyrilutamide, and alfatradiol have varied effectiveness and side effects.
The conversation discusses concerns about a new rule affecting orders of hair loss treatments like Minoxidil, finasteride, and RU58841. Users are worried about the impact on their ability to obtain these products.